What is it about?
This study compiled the results of six studies to compare the impacts and safety of Breezhaler® device compared to HandiHaler® device, and a placebo. The pooled data provided a deeper insight into the relevant safety concerns of the treatment options.
Featured Image
Photo by Andre Hunter on Unsplash
Why is it important?
Ensuring the safety of treatments is paramount to quality care outcomes. This work looked is important as it reviews the rate of adverse effects from the studies as well as post-market survivance giving a clear view of the treatment risks.
Perspectives
The analysis of post-market surveillance is key to maintain accountability and transparency in treatment options.
Professor Kenneth R Chapman
University of Toronto
Read the Original
This page is a summary of: Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data, International Journal of Chronic Obstructive Pulmonary Disease, August 2015, Dove Medical Press,
DOI: 10.2147/copd.s81266.
You can read the full text:
Contributors
The following have contributed to this page
